Intelligence Profile
Research Papers
Key Research Papers and Clinical Trials
Research on omega-3 EPA/DHA supplementation spans multiple health conditions, with recent studies examining both therapeutic applications and biomarker relationships.
Cardiovascular and Metabolic Health
A 2026 study in The Journal of Nutrition pooled results from four supplementation trials examining the relationship between omega-3 status (measured by the ω-3 Index) and inflammatory markers, specifically the neutrophil-lymphocyte ratio. The analysis found an inverse association, suggesting higher omega-3 levels may correspond to lower inflammatory burden.
Research published in Pharmacology & Therapeutics (2026) reviewed imaging studies examining how omega-3 fatty acids, along with fibrates and PCSK9 inhibitors, affect atherosclerotic plaque characteristics including burden, composition, and stability. This provides insights into potential mechanisms for cardiovascular protection.
Post-Surgical Applications
A triple-blind randomized controlled trial published in the Journal of Cachexia, Sarcopenia and Muscle (2026) investigated omega-3 supplementation for sarcopenia following bariatric surgery. This represents emerging research into omega-3s for muscle preservation in surgical populations, though specific sample sizes and outcomes were not detailed in the available information.
Pediatric Mental Health
A systematic review and biomarker-stratified meta-analysis in Frontiers in Public Health (2026) examined omega-3 supplementation for pediatric ADHD, specifically analyzing how baseline nutritional status affects treatment response. This approach of stratifying by biomarkers represents a more personalized medicine approach to omega-3 research.
Clinical Trial Landscape
Completed clinical trials include studies on omega-3s for type 2 diabetes (NCT00829569), major depressive disorder (NCT00816322), and acute myocardial infarction in elderly patients (NCT01841944). Currently recruiting trials are examining combinations of omega-3s with other compounds, such as tart cherry for aromatase inhibitor-related symptoms (NCT06123286).
Evidence Limitations
The available evidence summaries lack specific details about sample sizes, dosing protocols, and primary outcomes for most studies. More detailed study information would be needed to fully assess the strength and clinical relevance of these findings.
Note: This synthesis is based on available study titles and registry information. Consult healthcare providers for personalized medical advice regarding omega-3 supplementation.